On January 3, 2025, Aclarion, Inc. entered into a Securities Purchase Agreement to sell 3,380,276 shares of common stock at $0.142 per share in a registered direct offering. The offering, expected to close on January 6, 2025, aims to raise approximately $480,000 in gross proceeds.The company plans to use the net proceeds for market development, clinical evidence, product development, quality improvement, and general administrative support. Dawson James Securities, Inc. is acting as the sole placement agent, receiving a 7% cash fee of the aggregate gross proceeds.Aclarion, a healthcare technology company, leverages biomarkers and AI algorithms to help physicians identify chronic low back pain locations. The offering is made under an effective S-3 registration statement filed with the SEC on September 9, 2024, and declared effective on September 23, 2024.

On January 3, 2025, Aclarion, Inc. entered into a Securities Purchase Agreement to sell 3,380,276 shares of common stock at $0.142 per share in a registered direct offering. The offering, expected to close on January 6, 2025, aims to raise approximately $480,000 in gross proceeds.The company plans to use the net proceeds for market development, clinical evidence, product development, quality improvement, and general administrative support. Dawson James Securities, Inc. is acting as the sole placement agent, receiving a 7% cash fee of the aggregate gross proceeds.Aclarion, a healthcare technology company, leverages biomarkers and AI algorithms to help physicians identify chronic low back pain locations. The offering is made under an effective S-3 registration statement filed with the SEC on September 9, 2024, and declared effective on September 23, 2024.